Home » Newsletters » BioWorld Science

BioWorld Science

March 22, 2016

View Archived Issues

New variant detected in SIX3 gene in patient with holoprosencephaly

AstraZeneca provide early data on AZD-7594

ThromboGenics and Galapagos sign global and exclusive in-licensing agreement

Qu Biologics presents initial results from QBECO-01 trial

Phase III study of pegvaliase for treatment of PKU meets primary endpoint

FDA first to approve Anthim for inhalation anthrax

Theratechnologies and TaiMed Biologics sign exclusive agreement for ibalizumab

AVEO and CANbridge enter exclusive licensing agreement for AV-203 outside of North America

Oncolix initiates first-in-human study of Prolanta for ovarian cancer

Lupin announces MAP kinase inhibitors

First-in-human study explores ARX-788 for advanced breast cancer

Delta-Fly initiates phase I trial of DFP-13318 in advanced solid tumors

Transgenomic launches EGFR C797S mutation detector assay

Harvard University and Merck & Co. announce collaboration agreement to develop cancer therapeutics

Idelvion now available in U.S.

ContraVir initiates phase I/IIa trial of CMX-157 in chronic HBV infection

Evotec announces spin-off company Topas Therapeutics

FDA approves use of Roche's HCV RNA test to aid diagnosis of active HCV infection

Janssen and Genentech enter clinical trial collaboration to study daratumumab with atezolizumab

Biocept collaborates on trial to analyze biomarkers

Moberg announces phase III plans and agreement with Cadila for BUPI

Synairgen reports promising in vitro findings from LOXL2 inhibitor program for IPF

NCC, University of Tokyo and Daiichi Sankyo collaborate in malignant lymphoma research

TCTE3 shows potential as a biomarker for the diagnosis of pancreatobiliary tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...